fbpx

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo

Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.

Read Source
DonateMore InfoDonateMore Info
We cannot gather at a gala event this year, but a pandemic cannot stop us from joining together to ensure that the search to find a cure for gastric (stomach) cancer continues.

Join with us to fuel the next wave of progress.

Every contribution moves us closer to a cure.
Please join with us to fuel the next wave of progress. Together, we will defeat stomach cancer.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
X